Home Neoplasma Ahead of print neo_2018_171123N759

Journal info

6 times a year.
Founded: 1954
ISSN 0028-2685
ISSN 1338-4317 (online)

Published in English

Editorial Info
Abstracted and Indexed
Submission Guidelines

Select Journal

Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.


Title: The importance of serum osteopontin and stanniocalcin-1 in renal cell carcinoma

Abstract: To assess the prognostic importance of serum levels of osteopontin (OP), stanniocalcin-1 (SC), FGF-23, alpha Klotho and 25-OH-D at the time of diagnosis in renal cell carcinoma (RCC) patients a total of 56 RCC patients with staging ≥ pT1b were enrolled in a prospective study. The relationship between the serum level of the analysed parameters and recurrence-free survival (RFS), overall survival (OS) and cancer-specific survival (CSS) was examined. Control group consisted of 20 patients without cancer. Level of osteopontin, stanniocalcin-1, FGF-23 and alpha Klotho were determined by Enzyme-Linked Immunosorbent Assay (ELISA), 25-OH-D by chemiluminiscence immunoanalysis (CLIA). The follow-up period median was 46 months. Renal cell carcinoma recurred in 9 patients, 20 patients died during the follow-up, 12 of them from RCC. The level of osteopontin and stanniocalcin-1 varied between the control group and RCC patients (p = 0.02 and p = 0.0003, respectively). Higher levels of stanniocalcin-1 were detected in metastatic RCC group versus localized RCC group (p = 0.003).  Only stanniocalcin-1 level at the time of surgery was associated with RFS (p = 0.0004). Both OS and CSS were associated with the osteopontin, stanniocalcin-1 and FGF-23 preoperative level.  Patients with level of stanniocalcin-1 more than 1277 pg/ml and osteopontin level more than 100 ng / ml had 17.8 times higher and 7.9 times higher risk of dying due to RCC progression, respectivelly (p

Keywords: Renal cell carcinoma, osteopontin, stanniocalcin-1, overall survival, cancer-specific survival, recurrence-free survival
Published online: 19-Jun-2018
Year: , Volume: , Issue: Page From: , Page To:

download file

© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.